Skip to main content
OpenTrials

Clinical trial condition

Bacterial Infections

Explore clinical trials studying Bacterial Infections. Study availability and eligibility vary by location and protocol.

4,515 public trials 493 recruiting studies
Refine in advanced search Browse all conditions

Bacterial Infections trial results

Completed

Assess the Immune Response Following Primary Vaccination With GSK Biologicals' Tritanrix™-HepB/Hib-MenAC vs Tritanrix™-HepB/Hiberix™ Given at 6,10 & 14 Wks of Age to Infants Who Received Hepatitis B Vaccine at Birth

NCT00317122

Conditions
Actinomycetales Infections, Bacterial Infections, Bacterial Infections and Mycoses, +20 more
Locations
  • GSK Investigational Site Brits, South Africa
  • GSK Investigational Site Brits, South Africa
  • GSK Investigational Site Centurion, South Africa
  • GSK Investigational Site Ga-Rankuwa, South Africa
View Trial Details
Completed

Assess if Immune Response of GSK Biologicals' Tritanrix™-HepB/Hib-MenAC Given Without or With Hepatitis B Vaccine at Birth is at Least as Good as Tritanrix™-HepB/Hiberix™ Without Hepatitis B Vaccine at Birth, When Given to Healthy Infants

NCT00290303

Conditions
Actinomycetales Infections, Bacterial Infections, Bacterial Infections and Mycoses, +21 more
Locations
  • GSK Investigational Site Manila, Philippines
  • GSK Investigational Site Quezon City, Philippines
  • GSK Investigational Site Sampaloc, Manila, Philippines
View Trial Details
Completed

Study of a Booster Dose of Hib-MenC Conjugate Vaccine vs Infanrix Hexa When Given to 14 Month Old Subjects

NCT00323050

Conditions
Bacterial Infections, Bacterial Infections and Mycoses, Gram-Negative Bacterial Infections, +5 more
Locations
  • GSK Investigational Site Alcorcón, Spain
  • GSK Investigational Site Almeira, Spain
  • GSK Investigational Site Barcelona, Spain
  • GSK Investigational Site Barcelona, Spain
View all 16 locations
View Trial Details
Completed

Comparison of GSK Biologicals' DTaP-IPV Candidate Vaccine to DTaP and IPV Separately Administered Vaccines in Terms of Immune Response and Safety

NCT00263692

Conditions
Acellular Pertussis, Actinomycetales Infections, Bacterial Infections, +7 more
Locations
  • GSK Investigational Site Jonesboro, Arkansas, United States
  • GSK Investigational Site Fountain Valley, California, United States
  • GSK Investigational Site Oakland, California, United States
  • GSK Investigational Site Torrance, California, United States
View all 15 locations
View Trial Details
Completed

Assessment of GSK Biologicals' Tdap Candidate Vaccine Administered as a Booster (6th Dose) in Terms of Immunogenicity and Safety to Children and Adolescents Previously Vaccinated With Five Doses of an Acellular Pertussis-containing Vaccine.

NCT00263679

Conditions
Acellular Pertussis, Actinomycetales Infections, Bacterial Infections, +7 more
Locations
  • GSK Investigational Site Kehl, Baden-Wurttemberg, Germany
  • GSK Investigational Site Oberkirch, Baden-Wurttemberg, Germany
  • GSK Investigational Site Limburg an der Lahn, Hesse, Germany
  • GSK Investigational Site Erkrath, North Rhine-Westphalia, Germany
View all 13 locations
View Trial Details
Completed

Immunogenicity and Reactogenicity Study of BoostrixTM (dTpa) and Boostrix-IPV (dTpa-IPV)

NCT01294605

Conditions
Acellular Pertussis, Actinomycetales Infections, Bacterial Infections, +7 more
Locations
  • GSK Investigational Site Bruges, Belgium
  • GSK Investigational Site Leuven, Belgium
  • GSK Investigational Site Wilrijk, Belgium
  • GSK Investigational Site Rotterdam, Netherlands
View all 13 locations
View Trial Details

Related conditions